BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced ...

Approximately 15 million USD; Oryzon to validate epigenetic agents by applying a personalized medicine approach for rare and orphan diseases; Oryzon will explore Aggression in spe ...

Aptose Biosciences Inc. ("Aptose" or the "Company") , a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly ...